EUVIMEDEUVIMED entdecken
Crossref

Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials

Guotao Chu iD, Xiaochen Zhu iD, Jiaju Wu iD, Yike Tang iD, Jonathan Luu iD, Chunsheng He iD, Shu-Pang Huang, Liangang Liu, Hsin-Ju Hsieh

Clinical Pharmacology & Therapeutics · 2025-06 · 117 (6) · 1706-1717

DOI: 10.1002/cpt.3613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 27.02.2025. Verfasst von Guotao Chu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Global Biometrics & Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA. Hauptthemen laut MEDLINE: Clinical Trials as Topic, Neoplasms, Endpoint Determination, Medical Oncology. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Surrogate endpoints, such as progression‐free survival (PFS) and objective response rate (ORR), are increasingly used in oncology trials to expedite drug development and decision making. This paper evaluates the effectiveness of these surrogate endpoints by analyzing their correlations with overall survival (OS) across different cancer types, treatments, and therapy lines at both the patient and trial levels using an integrated dataset from Bristol Myers Squibb. At the patient level, correlation between OS and PFS was consistently stronger than those between OS and best overall response (BOR), suggesting that PFS may serve as a more reliable surrogate for OS. Melanoma patients exhibited the highest correlation between OS and BOR, and immune‐oncology (IO) therapy patients showed stronger correlations than those treated with chemotherapy. First‐line therapy patients demonstrated stronger correlations between BOR, PFS, and OS compared with second‐line or third‐line patients. At the trial level, the correlation between PFS hazard ratio (HR) and difference in ORR (∆ORR) was stronger than that between other endpoints. Melanoma studies exhibited strong correlations with significant P ‐values. IO therapy studies exhibited more consistent correlations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials as TopicNeoplasmsEndpoint DeterminationMedical OncologyAntineoplastic AgentsHumansProgression-Free SurvivalMelanomaTreatment Outcome

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Global Biometrics & Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.
  • Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts, USA.

ORCID-Profile: Guotao Chu, Xiaochen Zhu, Jiaju Wu, Yike Tang, Jonathan Luu, Chunsheng He

Zitieren

APA

Chu, G., Zhu, X., Wu, J., Tang, Y., Luu, J., He, C., Huang, S. P., Liu, L., & Hsieh, H. J. (2025). Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials. Clinical Pharmacology & Therapeutics, 117(6), 1706-1717. https://doi.org/10.1002/cpt.3613

Vancouver

Chu G, Zhu X, Wu J, Tang Y, Luu J, He C, et al. Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials. Clinical Pharmacology & Therapeutics. 2025;117(6):1706-1717. doi:10.1002/cpt.3613

BibTeX
@article{Chu2025,
  author = {Chu, Guotao and Zhu, Xiaochen and Wu, Jiaju and Tang, Yike and Luu, Jonathan and He, Chunsheng and Huang, Shu-Pang and Liu, Liangang and Hsieh, Hsin-Ju},
  title = {Assessing Correlation between Surrogate Endpoints and Overall Survival for Oncology Clinical Trials},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2025},
  volume = {117},
  number = {6},
  pages = {1706--1717},
  doi = {10.1002/cpt.3613}
}
Kostenlos starten →